Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

DelMar Pharma OK'd to Start Trial of Lead Drug in Ovarian Cancer Patients

publication date: Sep 19, 2017

DelMar Pharma was approved to start a Phase I trial of its lead molecule, VAL-083, in patients with ovarian cancer. The US trial is the second indication for VAl-083, which is already in US and China trials for refractory brain cancer. Several years ago, when DelMar started looking for a supplier of VAL-083, it discovered that Guangxi Wuzhou Pharma offered the drug in China for leukemia and lung cancer. They struck a partnership under which Wuzhou will provide global supplies of the drug to DelMar, while the two companies would partner on new indications of the drug in China. DelMar owns ex-China rights. DelMar is headquartered in Vancouver and has a clinical operations office in Menlo Park. More details....

Stock Symbol: (NSDQ: DMPI)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.